Wellcome Trust Sanger Institute

Name

Wellcome Trust Sanger Institute

Legal name

Genome Research Limited

Website

https://sanger.ac.uk

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Hinxton

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain

Revenue model

1. Commercial Licensing: Revenue generated from commercial licensing of COSMIC data to for-profit organizations including pharmaceutical companies, biotech firms, and diagnostic labs. Commercial users access data through QIAGEN's portal and pay licensing fees that fund continued research and development.
2. Wellcome Trust Funding: Core operational funding from Wellcome Trust, including a £10 million grant for the SynHG synthetic human genome project. Since 1992, Wellcome has invested to support bold, long-term discovery science at scale.
3. Collaborative Research Grants: Funding from major initiatives like the Virtual Biology Initiative ($500M from Biohub) and participation in large-scale international research collaborations that provide project-specific resources.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

The Wellcome Sanger Institute conducts large-scale genomic research and develops curated genomic databases and bioinformatics tools, anchored by COSMIC (Catalogue of Somatic Mutations in Cancer), the world's largest curated resource of somatic mutations in human cancer. It provides data access platforms, open-source mutational signature analysis tools, and operates large-scale research initiatives including the Darwin Tree of Life Project. The institute operates a dual-access model with free access for academic researchers and commercial licensing managed through QIAGEN for for-profit organizations.

Product overview

The Wellcome Sanger Institute operates a portfolio of genomic research platforms and scientific tools, anchored by COSMIC (Catalogue of Somatic Mutations in Cancer), the world's largest curated resource of somatic mutations in human cancer. COSMIC encompasses multiple integrated sub-products including COSMIC-3D for structural analysis, the Cancer Gene Census for cataloging cancer driver genes, COSMIC Mutational Signatures for analyzing mutational processes across samples, and SigProfiler bioinformatics tools for de novo extraction and assignment of mutational signatures. The Institute also maintains the eDAM2 data access platform and is transitioning to Sapio LIMS for workflow management. Its research programs include the Darwin Tree of Life Project (biodiversity genome sequencing), Project JAGUAR (proteomic profiling with Nomic Bio), Quantum Pangenome (quantum computing for genomics), NanoSeq (rare mutation detection), and collaborative initiatives such as the Virtual Biology Initiative and CRISPR target validation. COSMIC data is freely available for academic use via Sanger Download Sites, with commercial licensing managed through QIAGEN's Digital Insights portal.

Differentiator

Problem solved

Functional benefit

Brands

• COSMIC (Catalogue of Somatic Mutations in Cancer): The world's largest and most comprehensive resource for exploring the impact of somatic mutations in human cancer, including mutational signatures, cancer gene census, and related genomic data.

Products and services

• COSMIC (Catalogue of Somatic Mutations in Cancer) The world's largest and most comprehensive curated resource for exploring the impact of somatic mutations in human cancer. Provides searchable databases, bioinformatics tools, mutational signature analysis, gene curation, and data downloads for academic and commercial users, supporting cancer research and drug development globally.
• COSMIC-3D Structural visualization and analysis module within COSMIC that enables exploration of the 3D spatial context of somatic mutations in cancer proteins and genomes, supporting drug discovery and functional interpretation of cancer genomics data.
• COSMIC Mutational Signatures Curated reference set of high-confidence mutational signatures across human cancer, including Single Base Substitutions (SBS, v3.6), Doublet Base Substitutions (DBS), Insertions and Deletions (ID), Copy Number Variations (CN), Structural Variants (SV), and RNA Single Base Substitutions (RNA-SBS).
• SigProfiler Bioinformatics Tools Suite of open-source bioinformatics tools for performing comprehensive mutational signature analysis, including SigProfilerMatrixGenerator, SigProfilerPlotting, SigProfilerExtractor, SigProfilerAssignment, SigProfilerSimulator, SigProfilerClusters, and SigProfilerTopography. Available in both Python and R environments.
• eDAM2 (electronic Data Access Mechanism) Electronic Data Access Mechanism used by the Wellcome Sanger Institute to manage and grant access to human genomic data for bonafide researchers from legitimate research organisations, ensuring participant privacy is protected through controlled data access.

Quantifiable outcome

• 300,000+ somatic mutations documented
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability9 records

Feature6 records

Partnerships

Eleven partnerships are on record, tiered core and flagship.

• Nomic Bio Inc.coreStrategic or Co-development Partner · 16 June 2026Research collaboration to perform large-scale proteomic profiling of over 1,500 PBMC samples through Project JAGUAR. Using Nomic's Omni 1000 platform to generate quantitative protein expression data, integrating proteomic data with existing genomic and transcriptomic datasets to build a functional atlas of human immune variation focused on genetically diverse Latin American populations.
• NVIDIAcoreTechnology or Integration · 2 May 2026Technology partner providing computing power to process datasets needed for training AI systems that can simulate cellular behavior as part of the Virtual Biology Initiative.
• Biohub (Mark Zuckerberg and Priscilla Chan)flagshipStrategic or Co-development Partner · 29 April 2026Five-year Virtual Biology Initiative with $500 million commitment to create data foundation and technologies for building predictive AI models of the human cell. Sanger is one of multiple leading institutions (Allen Institute, Arc Institute, Broad Institute, Human Cell Atlas, Human Protein Atlas) partnering in this global effort. NVIDIA serves as key technology partner for accelerated computing infrastructure.
• Natural History MuseumcoreStrategic or Co-development PartnerCoordinating institution for the £3 billion Darwin Tree of Life Project which sequences DNA of all complex life across the UK and Ireland. Project has delivered nearly £3 billion in projected economic value and generated 30% of the world's biodiversity genomes.
• IBMcoreTechnology or IntegrationPartnership for quantum computing applications in genomics. IBM provides quantum hardware access including 156-qubit Heron processor for the Quantum Pangenome project. Scientists from Sanger have encoded complete genomes on IBM quantum processors as part of Q4Bio program.
• Google DeepMind and Google.orgcoreStrategic or Co-development PartnerAI consortium for genomics to generate large-scale genomic datasets and power AI-driven discoveries. Partnership announced on Sanger's website.
• Five UK UniversitiescoreStrategic or Co-development PartnerMulti-centre SynHG (Synthetic Human Genome) research project receiving £10 million in funding from Wellcome. Led by Professor Jason Chin, developing foundational tools for synthesizing large human genomes with a five-year timeline.
• QIAGENcoreChannel Partner/ Reseller/ DistributorCommercial distribution partner for COSMIC data licensing. QIAGEN manages commercial licenses to COSMIC for commercial/for-profit organisations through their QDI Portal, enabling the database's self-sustaining business model.
• Cancer Grand ChallengescoreStrategic or Co-development PartnerPartnership with Cancer Grand Challenges Mutographs team for curating and analyzing topographical features in cancer genomes. Collaborates on the Cancer Gene Census and Cancer Mutation Census.
• ICGC/TCGA Pan-Cancer Analysis of Whole Genomes NetworkcoreStrategic or Co-development PartnerInternational consortium providing large-scale cancer genome data used for mutational signature extraction and validation. Data from over 23,000 cancer patients informing COSMIC's reference signatures.
• The Cancer Genome Atlas (TCGA)coreStrategic or Co-development PartnerProvides allele-specific copy number profiles and genomic data used for extracting COSMIC mutational signatures across multiple cancer types.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Arc Institute: Non-profit research organization co-founded by Patrick Collison focused on complex disease and computational biology. Co-participant in the Virtual Biology Initiative and a peer in next-generation AI-driven biology research, though smaller and younger than Sanger.

Direct peers

• The Jackson Laboratory: Independent non-profit biomedical research institute focused on genetics, genomics, and mouse models for human disease. Comparable as a non-profit research powerhouse producing foundational genetic and genomic resources for the global community.
• Broad Institute: MIT/Harvard-affiliated genomics and biomedical research institute conducting large-scale genomic sequencing, functional genomics, and computational biology. Direct peer as both are top-tier non-profit genome research centers producing foundational datasets (e.g., gnomAD, Cell Atlas) used globally.
• HudsonAlpha Institute for Biotechnology: Non-profit genomics research institute combining large-scale sequencing, clinical genomics, and bioinformatics. Comparable as both conduct genomic discovery research, run sequencing facilities, and translate findings into clinical/diagnostic applications.
• New York Genome Center: Independent non-profit genomics research organization with academic and industry partners, conducting large-scale sequencing, neurogenomics, and computational biology. Comparable scale and mission as a hub for collaborative genomic research.
• Allen Institute: Large-scale non-profit research organization producing comprehensive atlas-level datasets (e.g., Allen Brain Atlas, cell atlases). Co-participant with Sanger in the Virtual Biology Initiative and comparable in mission of producing foundational open scientific resources at scale.
• European Bioinformatics Institute (EMBL-EBI): EMBL-EBI hosts major open-access biological databases (Ensembl, UniProt, ENA) and provides bioinformatics infrastructure on the same Wellcome Genome Campus as Sanger. Highly comparable as both curate and disseminate large-scale genomic and molecular data to global research communities.

Regional players

• BGI Group: China-based genomics organization conducting large-scale sequencing, BGE biodiversity genome project, and clinical sequencing services. Comparable as a globally operating non-commercial and commercial genomics enterprise, but primarily serves Asia.

Others

• QIAGEN: Commercial partner of Sanger for COSMIC distribution, and a major player in molecular diagnostics and sample-preparation technologies. Comparable as it serves the same oncology R&D customer base, with overlapping bioinformatics offerings (QDI, IPA).

Broad incumbents

• Illumina: Dominant commercial provider of next-generation sequencing platforms used by Sanger and similar institutes globally. Comparable through shared genomics customer base and ecosystem position, though Illumina operates as a commercial tools provider rather than a research institute.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/sangerinstitute
• LinkedInlinkedin.com/company/wellcome-trust-sanger-institute
• Xx.com/sangerinstitute

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wellcome Trust Sanger Institute